Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
KCT0011734 Everolimus Vascular Tissue Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
KCT0011734 clinical trial report covering Everolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477548 Everolimus Port-Wine Stain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477548 clinical trial report covering Everolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07478744 SYT-510 Generalized anxiety disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07478744 clinical trial report covering SYT-510, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477782 Fecal microbiota transplantation(Assistance Publique des Hôpitaux de Paris) Cholangitis, Sclerosing Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477782 clinical trial report covering Fecal microbiota transplantation(Assistance Publique des Hôpitaux de Paris), Phase 2, endpoints, sponsor, geogra
Latest Hotspot
8 min read
NCT07480863 Zuberitamab Marginal Zone B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07480863 clinical trial report covering Zuberitamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477704 Alirocumab Hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477704 clinical trial report covering Alirocumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07480096 Lemborexant Sleep Initiation and Maintenance Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07480096 clinical trial report covering Lemborexant, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476287 SSGJ-707 Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476287 clinical trial report covering SSGJ-707, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120728 Regorafenib Metastatic hepatocellular carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120728 clinical trial report covering Regorafenib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120703 TAF-001 Psoriasis vulgaris Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120703 clinical trial report covering TAF-001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07480850 Obinutuzumab Diffuse large B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07480850 clinical trial report covering Obinutuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07481058 Canlitinib Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07481058 clinical trial report covering Canlitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.